Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-08-14

Clinical Trial Update: Sunitinib in Treating Patients With Idiopathic Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial of sunitinib in patients with primary myelofibrosis was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2012-08-14